Skip to Main Content

Paper Details

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
Neuro Oncol
63
2018
Cabozantinib, GBM, MET, Patients, VEGFR2, advanced solid tumors, cabozantinib, diarrhea, fatigue, glioblastoma, palmar-plantar erythrodysesthesia syndrome, patients, progressive, tyrosine, tyrosine kinase, vascular endothelial growth factor receptor 2
Author NameAffiliation
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, J.D.) The University of Texas MD Anderson Cancer Center, Texas (J.dG.) University of California, Helen Diller Cancer Center Building, California (M.D.P.) Duke University, A.D.) Neuro-Oncology Center, University of Virginia Health System, Virginia (D.S.) University of Washington, Fred Hutchinson Cancer Research Center, R.W.) The Ronald Reagan university of california los angeles Medical Center
John F de GrootCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, J.D.) The University of Texas MD Anderson Cancer Center, Texas (J.dG.) University of California, Helen Diller Cancer Center Building, California (M.D.P.) Duke University, A.D.) Neuro-Oncology Center, University of Virginia Health System, Virginia (D.S.) University of Washington, Fred Hutchinson Cancer Research Center, R.W.) The Ronald Reagan university of california los angeles Medical Center
Michael D PradosCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, J.D.) The University of Texas MD Anderson Cancer Center, Texas (J.dG.) University of California, Helen Diller Cancer Center Building, California (M.D.P.) Duke University, A.D.) Neuro-Oncology Center, University of Virginia Health System, Virginia (D.S.) University of Washington, Fred Hutchinson Cancer Research Center, R.W.) The Ronald Reagan university of california los angeles Medical Center
Michael D PradosCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, J.D.) The University of Texas MD Anderson Cancer Center, Texas (J.dG.) University of California, Helen Diller Cancer Center Building, California (M.D.P.) Duke University, A.D.) Neuro-Oncology Center, University of Virginia Health System, Virginia (D.S.) University of Washington, Fred Hutchinson Cancer Research Center, R.W.) The Ronald Reagan university of california los angeles Medical Center
David SchiffCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, J.D.) The University of Texas MD Anderson Cancer Center, Texas (J.dG.) University of California, Helen Diller Cancer Center Building, California (M.D.P.) Duke University, A.D.) Neuro-Oncology Center, University of Virginia Health System, Virginia (D.S.) University of Washington, Fred Hutchinson Cancer Research Center, R.W.) The Ronald Reagan university of california los angeles Medical Center
Tom MikkelsenCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, J.D.) The University of Texas MD Anderson Cancer Center, Texas (J.dG.) University of California, Helen Diller Cancer Center Building, California (M.D.P.) Duke University, A.D.) Neuro-Oncology Center, University of Virginia Health System, Virginia (D.S.) University of Washington, Fred Hutchinson Cancer Research Center, R.W.) The Ronald Reagan university of california los angeles Medical Center
Tom MikkelsenCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, J.D.) The University of Texas MD Anderson Cancer Center, Texas (J.dG.) University of California, Helen Diller Cancer Center Building, California (M.D.P.) Duke University, A.D.) Neuro-Oncology Center, University of Virginia Health System, Virginia (D.S.) University of Washington, Fred Hutchinson Cancer Research Center, R.W.) The Ronald Reagan university of california los angeles Medical Center
Timothy F CloughesyCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, J.D.) The University of Texas MD Anderson Cancer Center, Texas (J.dG.) University of California, Helen Diller Cancer Center Building, California (M.D.P.) Duke University, A.D.) Neuro-Oncology Center, University of Virginia Health System, Virginia (D.S.) University of Washington, Fred Hutchinson Cancer Research Center, R.W.) The Ronald Reagan university of california los angeles Medical Center
Timothy F CloughesyCenter for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, J.D.) The University of Texas MD Anderson Cancer Center, Texas (J.dG.) University of California, Helen Diller Cancer Center Building, California (M.D.P.) Duke University, A.D.) Neuro-Oncology Center, University of Virginia Health System, Virginia (D.S.) University of Washington, Fred Hutchinson Cancer Research Center, R.W.) The Ronald Reagan university of california los angeles Medical Center
  • 1 - 9

Datasets

Release 1.2